Bone Metastases Drive Rapid Muscle Wasting and Poorer Survival in Kidney Cancer

When cancer spreads to bone, it does far more than weaken the skeleton. A new study of nearly 300 patients with kidney cancer suggests that bone metastases may act as an engine of whole-body wasting, accelerating the loss of skeletal muscle at a pace that dwarfs what is seen in patients whose disease remains localized or spreads only to soft tissues. The findings, published in the Journal of Cachexia, Sarcopenia and Muscle, add weight to a growing body of evidence that the tumor–bone axis is not merely a site of painful complications but an active participant in the systemic decline of cancer patients.

Cachexia, the wasting syndrome at the center of this research, is one of the most feared and least understood consequences of advanced malignancy. Characterized by the progressive loss of muscle and, often, fat and bone mass, it affects up to 80 percent of patients with advanced cancer and is implicated in an estimated 20 to 40 percent of all cancer deaths. The syndrome impairs skeletal, diaphragmatic and even cardiac muscle function, erodes tolerance to systemic therapy, and, despite recent progress with experimental agents such as the GDF-15 inhibitor ponsegromab, still has no FDA-approved treatment. As cancer survival improves overall, the clinical burden of cachexia is rising, making the search for its drivers increasingly urgent.

Metastatic bone disease is a common complication across many solid tumors, present in roughly 30 percent of patients with metastatic disease at the time of diagnosis and in as many as 70 percent at autopsy. Clinically, management has traditionally centered on palliating pain and preventing fractures. Yet laboratory work has hinted at broader consequences: tumor–bone interactions can invigorate metastatic growth, and bone-derived factors released during metastatic colonization have been shown to promote muscle wasting in animal models. What has been missing is rigorous clinical evidence that bone metastases are associated with measurable, longitudinal muscle loss in patients.

Kidney cancer offered the researchers an ideal setting to close that gap. Clear cell renal cell carcinoma accounts for nearly 90 percent of kidney cancer cases, and both cachexia and skeletal involvement are frequent: approximately 40 percent of patients develop cachexia, and 30 to 40 percent experience bone metastases during the course of disease. Kidney cancer also carries a relatively favorable prognosis compared with many other solid tumors, providing an extended window in which wasting can influence outcomes and, potentially, be therapeutically targeted.

The study, conducted at Indiana University, retrospectively analyzed 293 adults diagnosed with clear cell renal cell carcinoma between 2010 and 2019. Patients were divided into three groups at diagnosis: those with localized disease, those with metastases outside bone, and those with bone metastases. To quantify body composition over time, the team turned to an artificial intelligence–assisted segmentation platform called Data Analysis Facilitation Suite, which measures skeletal muscle, subcutaneous fat, visceral fat and bone cross-sectional area at the midpoint of the third lumbar vertebra on routine CT scans. Ninety-nine patients had serial scans suitable for longitudinal analysis, allowing the researchers to calculate annualized percent change in each tissue compartment.

The results were striking. At diagnosis, median skeletal muscle cross-sectional area was similar across the three groups, at roughly 151 to 165 square centimeters. Over time, however, the trajectories diverged sharply. Patients with localized disease lost muscle at a median rate of just 0.8 percent per year, and those with extraosseous metastases lost 1.2 percent per year. Patients with bone metastases, by contrast, lost muscle at a median rate of 7.5 percent per year. In multiple variable linear regression adjusting for age, sex, race, chemotherapy, immunotherapy and bone-modifying agents, the presence of osseous metastases was independently associated with an additional 20.9 percent loss of skeletal muscle per year compared with localized disease.

The wasting in bone-metastasis patients was not confined to muscle. Subcutaneous fat declined by 5.1 percent per year in this group, compared with modest changes in the other cohorts, and visceral adipose tissue fell by 15.6 percent per year. Bone cross-sectional area itself decreased by 3.6 percent per year in patients with osseous disease while increasing slightly in the other groups, a pattern consistent with prior reports of bone loss in cancer and suggestive of a systemic musculoskeletal disturbance that extends beyond the sites of metastatic deposits.

Survival analysis reinforced the clinical significance of these measurements. Median follow-up for the cohort was 672 days, during which 144 patients died. One-year overall survival was 88.1 percent for localized disease, 72.3 percent for extraosseous metastases and just 53.3 percent for bone metastases. Five-year survival told a similar story: 80.0 percent for localized disease versus 30.7 percent for patients with skeletal involvement. When the researchers stratified outcomes by the rate of muscle loss, the differences were even more dramatic. Patients losing more than 20 percent of their skeletal muscle per year had a one-year survival of only 30.7 percent and no survivors at five years, compared with one-year survival above 90 percent among patients with little or no muscle loss.

In Cox proportional hazards modeling adjusted for age, chemotherapy, immunotherapy and changes in fat compartments, both bone metastatic disease and skeletal muscle loss remained independently associated with death. Osseous metastases carried a hazard ratio of 15.8 relative to localized disease, while each additional percentage point of annualized muscle loss raised the hazard of death by 2 percent. Notably, 38.2 percent of patients in the osseous group exceeded the 20 percent annual muscle-loss threshold, compared with 13.9 percent of those with extraosseous metastases and only 3.4 percent of those with localized disease.

The authors caution that the study is retrospective, single-institution and subject to the biases inherent in chart review, and that shorter follow-up among patients with metastatic disease may have influenced the longitudinal analyses. Whether bone metastases directly cause muscle wasting or simply mark more advanced systemic disease remains uncertain. Still, preclinical work offers plausible mechanisms: studies in mouse models have shown that transforming growth factor beta released from bone metastases disrupts ryanodine receptor function in muscle, impairing contractility and promoting weakness. If such tumor–bone–muscle pathways operate in patients, kidney cancer, with its relatively long treatment window and high rate of skeletal involvement, could become a rational setting for early trials of cachexia-directed interventions, from structured exercise and rehabilitation to drugs designed to halt the wasting cascade before it becomes irreversible.

Subject of Research: The association between metastatic bone disease, longitudinal skeletal muscle loss and survival in clear cell renal cell carcinoma

Article Title: Metastatic Bone Disease Is Associated With Longitudinal Muscle Loss and Reduced Survival in Kidney Cancer

Article References: Poirier, J.-L., Jines, S. T., Silverman, L. M., Kambrath, A. V., Wurtz, L. D., Zimmers, T. A., & Collier, C. D. (2026). Metastatic Bone Disease Is Associated With Longitudinal Muscle Loss and Reduced Survival in Kidney Cancer. Journal of Cachexia, Sarcopenia and Muscle, 17(5), Article e70400. https://doi.org/10.1002/jcsm.70400

Image Credits: AI Generated

DOI: 10.1002/jcsm.70400

Keywords: kidney cancer, renal cell carcinoma, bone metastases, cachexia, sarcopenia, skeletal muscle loss, body composition, CT imaging, artificial intelligence, survival, cancer wasting syndrome, tumor-bone interaction